

MCMS RESOLUTION: Support for ending the sole domination of the National Institute on Drug Abuse (NIDA) and to allow privately-funded FDA-regulated clinical trials on Cannabis to proceed without unwarranted barriers.

INTRODUCED BY: Maricopa County Medical Society

SUBJECT: NIDA's sole authority and barriers to the advancement of essential Cannabis research

WHEREAS, at least 16 states have legalized the use of medical marijuana; and

WHEREAS, the federal government classifies marijuana as a Schedule I controlled substance; and

WHEREAS, a Schedule I controlled substance means that the substance has no recognized medicinal value, a classification that seriously impedes or prevents scientific research on the benefits and risks of the medicinal and recreational use of marijuana; and

WHEREAS, the Oregon Board of Pharmacy voted to change marijuana to a Schedule II controlled substance, a classification that recognizes medicinal value but with a high risk of abuse; and

WHEREAS, the appropriate controlled substance classification of marijuana should be based on scientific, pharmacological evidence and studies; and

WHEREAS, one year ago, the FDA approved our MJ/PTSD study; however, the National Institute on Drug Abuse refused to provide federally-grown marijuana to ours and other Food and Drug Administration-approved research protocols seeking to measure the extent to which marijuana helps combat veterans with their post-traumatic stress disorder; and

WHEREAS, rescheduling resolutions are wasteful and misguided, as proven by California's MJ Rescheduling Resolution. The federal government will not reschedule without Phase 3 clinical data, nor should it. Without getting NIDA to automatically provide marijuana to all FDA/DEA/IRB approved protocols, or better yet having the DEA approve an MJ Cultivation License for UMass' Professor Craker, nothing will change regarding research; therefore be it,

RESOLVED, that ArMA should urge the following policy to our AZ Congressional Delegation through our local lobbying department. Once the protocol for privately-funded marijuana research has been reviewed and approved by the Food and Drug Administration and relevant Independent Review Board and the practitioner has obtained registration from the Drug Enforcement Administration, the National Institute of Drug Abuse shall, without further evaluation of the research protocol, supply marijuana for the research, at cost, upon the practitioner's proper application.